UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 (State or Other Jurisdiction ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President of Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Maury Raycroft - Jefferies Troy Langford - TD Cowen Luca Issi - RBC Capital Kosta ...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.48%. A quarter ago, it was expected that this company would post a loss of $1.47 per share when it actually produced a loss of $1.46, delivering a surprise of 0.68%.Over the last four quarters, the company h ...

Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress - Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy - Aligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to review of IND application; expect to initiate the study by year- end - Plan to present new clinic ...

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2024 financial results and operational highlights in a conference call on May 9, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants sh ...

Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-upIntellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation fr ...

Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-up Intellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral presentation f ...

Intellia Therapeutics, Inc. (NTLA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, ...

Intellia Therapeutics, Inc. (NTLA) announced that it has dosed the first patient in the phase III MAGNITUDE study evaluating its investigational in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis, a rare and fatal disease that can lead to heart failure.The double-blind and placebo-controlled MAGNITUDE study will evaluate the safety and efficacy of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy.The company started dosing in the phase III MAGNIT ...

CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment of transthyr ...